AGEN
Agenus Inc.
Price Chart
Latest Quote
$5.00
-0.01 (-0.20%)
Current Price
| Previous Close | $5.01 |
| Open | $5.00 |
| Day High | $5.28 |
| Day Low | $4.67 |
| Volume | 2,691,805 |
Stock Information
| Shares Outstanding | 41.64M |
| Total Debt | $41.07M |
| Cash Equivalents | $35.00M |
| Revenue | $123.87M |
| Net Income | $64.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $208.63M |
| P/E Ratio | 2.43 |
| EPS (TTM) | $2.06 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $207.94M |
| Sales | $123.87M |
| Income | $64.39M |
| Book/sh | $-5.74 |
| Cash/sh | $0.84 |
| Employees | 81 |
Financial Ratios
| Quick Ratio | 0.36 |
| Current Ratio | 0.38 |
Returns & Margins
| ROA | 2.53% |
| Gross Margin | 97.39% |
| Operating Margin | 44.62% |
| Profit Margin | 52.16% |
Ownership
| Insider Ownership | 6.73% |
| Institutional Ownership | 23.74% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.18 |
| PEG | 1.44 |
| P/S | 1.68 |
| P/B | -0.87 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $30.00 |
Technical Indicators
| SMA20 | $3.70 |
| SMA50 | $3.48 |
| SMA200 | $3.67 |
| RSI | 69.49 |
| ATR | 0.7436 |
| Shares Float | 38.85M |
| Short Float | 14.58% |
| Short Ratio | 7.13 |
| Volatility | 1.55 |
| Rel Volume | 0.17 |
Performance History
| Week | +49.55% |
| Month | +68.12% |
| Quarter | +7.97% |
| 6 Months | +7.05% |
| YTD | +55.11% |
| Year | -21.23% |
| 3 Years | -86.68% |
| 5 Years | -95.47% |
| 10 Years | -94.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $5.01 | 1,727,500 |
| 2026-07-16 | $5.00 | 2,696,500 |
| 2026-07-15 | $5.01 | 4,491,100 |
| 2026-07-14 | $5.08 | 11,111,000 |
| 2026-07-13 | $6.12 | 174,277,900 |
| 2026-07-10 | $3.35 | 833,400 |
| 2026-07-09 | $3.24 | 654,200 |
| 2026-07-08 | $3.25 | 797,500 |
| 2026-07-07 | $3.50 | 1,164,300 |
| 2026-07-06 | $3.41 | 547,900 |
| 2026-07-02 | $3.49 | 680,400 |
| 2026-07-01 | $3.41 | 660,100 |
| 2026-06-30 | $3.06 | 644,500 |
| 2026-06-29 | $3.15 | 947,200 |
| 2026-06-26 | $3.03 | 5,006,300 |
| 2026-06-25 | $2.88 | 594,200 |
| 2026-06-24 | $2.92 | 625,200 |
| 2026-06-23 | $3.07 | 438,600 |
| 2026-06-22 | $3.04 | 476,100 |
| 2026-06-18 | $3.00 | 868,100 |
About Agenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFÃ TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
đ° Latest News
Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing
Simply Wall St. âĸ 2026-07-17T20:11:21Z
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
Zacks âĸ 2026-07-14T15:57:00Z
Agenus stock doubles as biotech narrows Phase 3 bet
TheStreet âĸ 2026-07-14T14:17:00Z
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Zacks âĸ 2026-07-14T12:15:00Z
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-07-14T10:15:27Z
AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment
Stocktwits âĸ 2026-07-13T18:25:00Z
Agenus shares surge as company secures up to $340M to advance colon cancer trial
Proactive âĸ 2026-07-13T16:53:00Z
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
MarketBeat âĸ 2026-07-13T14:02:46Z
Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)
InvestorsHub âĸ 2026-07-13T12:25:37Z
Agenus surges on study pivot; Apnimed lines up an IPO
BioPharma Dive âĸ 2026-07-13T11:46:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $80,360,000 | $156,014,000 | $237,680,000 | $197,259,000 |
| Cost Of Revenue | $80,360,000 | $156,014,000 | $237,680,000 | $197,259,000 |
| Total Revenue | $114,196,000 | $103,463,000 | $156,314,000 | $98,024,000 |
| Operating Revenue | $5,608,000 | $2,485,000 | $41,742,000 | $52,739,000 |
| Expenses | ||||
| Interest Expense | $55,273,000 | $117,626,000 | $97,925,000 | $61,863,000 |
| Total Expenses | $134,752,000 | $227,892,000 | $316,419,000 | $278,266,000 |
| Other Income Expense | $72,746,000 | $9,784,000 | $593,000 | $11,449,000 |
| Other Non Operating Income Expenses | $-2,220,000 | $5,830,000 | $37,000 | $12,571,000 |
| Net Non Operating Interest Income Expense | $-55,273,000 | $-117,626,000 | $-97,925,000 | $-61,863,000 |
| Interest Expense Non Operating | $55,273,000 | $117,626,000 | $97,925,000 | $61,863,000 |
| Operating Expense | $54,392,000 | $71,878,000 | $78,739,000 | $81,007,000 |
| General And Administrative Expense | $54,392,000 | $71,878,000 | $78,739,000 | $81,007,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $115,000 | $-227,212,000 | $-245,761,000 | $-220,074,000 |
| Net Interest Income | $-55,273,000 | $-117,626,000 | $-97,925,000 | $-61,863,000 |
| Normalized Income | $-101,196,000 | $-231,166,000 | $-246,317,000 | $-218,952,000 |
| Net Income From Continuing And Discontinued Operation | $115,000 | $-227,212,000 | $-245,761,000 | $-220,074,000 |
| Total Operating Income As Reported | $-20,169,000 | $-120,475,000 | $-159,549,000 | $-179,427,000 |
| Net Income Common Stockholders | $-101,000 | $-227,427,000 | $-245,974,000 | $-220,286,000 |
| Net Income | $115,000 | $-227,212,000 | $-245,761,000 | $-220,074,000 |
| Net Income Including Noncontrolling Interests | $-3,083,000 | $-232,271,000 | $-257,437,000 | $-230,656,000 |
| Net Income Continuous Operations | $-3,083,000 | $-232,271,000 | $-257,437,000 | $-230,656,000 |
| Pretax Income | $-3,083,000 | $-232,271,000 | $-257,437,000 | $-230,656,000 |
| Special Income Charges | $101,311,000 | $3,954,000 | $556,000 | $-1,122,000 |
| Earnings From Equity Interest | $-26,345,000 | $0 | $0 | - |
| Operating Income | $-20,556,000 | $-124,429,000 | $-160,105,000 | $-180,242,000 |
| Gross Profit | $33,836,000 | $-52,551,000 | $-81,366,000 | $-99,235,000 |
| Per Share | ||||
| Diluted EPS | $0.00 | $-10.59 | $-13.75 | $-15.64 |
| Basic EPS | $0.00 | $-10.59 | $-13.75 | $-15.64 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-39,122,000 | $-105,256,000 | $-146,480,000 | $-160,725,000 |
| Total Unusual Items | $101,311,000 | $3,954,000 | $556,000 | $-1,122,000 |
| Total Unusual Items Excluding Goodwill | $101,311,000 | $3,954,000 | $556,000 | $-1,122,000 |
| Reconciled Depreciation | $9,999,000 | $13,343,000 | $13,588,000 | $6,946,000 |
| EBITDA (Bullshit earnings) | $62,189,000 | $-101,302,000 | $-145,924,000 | $-161,847,000 |
| EBIT | $52,190,000 | $-114,645,000 | $-159,512,000 | $-168,793,000 |
| Diluted Average Shares | $29,734,000 | $21,473,000 | $17,894,000 | $14,087,000 |
| Basic Average Shares | $29,734,000 | $21,473,000 | $17,894,000 | $14,087,000 |
| Diluted NI Availto Com Stockholders | $-101,000 | $-227,427,000 | $-245,974,000 | $-220,286,000 |
| Preferred Stock Dividends | $216,000 | $215,000 | $213,000 | $212,000 |
| Minority Interests | $3,198,000 | $5,059,000 | $11,676,000 | $10,582,000 |
| Gain On Sale Of Business | $100,924,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $-387,000 | $-3,954,000 | $-556,000 | $-815,000 |
| Selling General And Administration | $54,392,000 | $71,878,000 | $78,739,000 | $81,007,000 |
| Other Gand A | $54,392,000 | $71,878,000 | $78,739,000 | $81,007,000 |
| Other Special Charges | - | - | - | $1,937,000 |
Fetched: 2026-07-09
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-298,240,000 | $-353,848,000 | $-189,465,000 | $-92,973,000 |
| Total Assets | $226,798,000 | $226,271,000 | $313,913,000 | $413,556,000 |
| Total Non Current Assets | $93,362,000 | $180,697,000 | $201,497,000 | $200,434,000 |
| Other Non Current Assets | $3,307,000 | $5,834,000 | $9,336,000 | $4,453,000 |
| Non Current Accounts Receivable | $15,435,000 | - | - | - |
| Goodwill And Other Intangible Assets | $27,129,000 | $27,468,000 | $29,134,000 | $31,695,000 |
| Other Intangible Assets | $3,037,000 | $3,376,000 | $4,411,000 | $6,228,000 |
| Current Assets | $133,436,000 | $45,574,000 | $112,416,000 | $213,122,000 |
| Other Current Assets | $1,089,000 | $2,415,000 | $2,372,000 | $3,194,000 |
| Assets Held For Sale Current | $121,554,000 | $0 | - | - |
| Prepaid Assets | $785,000 | $2,315,000 | $8,098,000 | $13,829,000 |
| Receivables | $7,010,000 | $407,000 | $25,836,000 | $2,741,000 |
| Notes Receivable | $5,179,000 | $0 | - | - |
| Accounts Receivable | $1,831,000 | $407,000 | $25,836,000 | $2,741,000 |
| Cash Cash Equivalents And Short Term Investments | $2,998,000 | $40,437,000 | $76,110,000 | $193,358,000 |
| Cash And Cash Equivalents | $2,998,000 | $40,437,000 | $76,110,000 | $178,674,000 |
| Debt | ||||
| Net Debt | $41,657,000 | - | - | - |
| Total Debt | $55,899,000 | $94,870,000 | $88,469,000 | $78,428,000 |
| Long Term Debt And Capital Lease Obligation | $10,108,000 | $85,024,000 | $75,279,000 | $75,910,000 |
| Current Debt And Capital Lease Obligation | $45,791,000 | $9,846,000 | $13,190,000 | $2,518,000 |
| Current Debt | $44,655,000 | $2,698,000 | $146,000 | $575,000 |
| Other Current Borrowings | $10,457,000 | $2,552,000 | - | $429,000 |
| Long Term Debt | - | $30,473,000 | $12,768,000 | $12,584,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $504,659,000 | $532,695,000 | $462,295,000 | $468,458,000 |
| Total Non Current Liabilities Net Minority Interest | $181,170,000 | $311,294,000 | $206,398,000 | $279,506,000 |
| Other Non Current Liabilities | $169,919,000 | $225,127,000 | $129,976,000 | $202,453,000 |
| Non Current Deferred Liabilities | $1,143,000 | $1,143,000 | $1,143,000 | $1,143,000 |
| Current Liabilities | $323,489,000 | $221,401,000 | $255,897,000 | $188,952,000 |
| Other Current Liabilities | $169,594,000 | $121,852,000 | $141,210,000 | $101,486,000 |
| Current Deferred Liabilities | $0 | $31,000 | $18,000 | $12,269,000 |
| Current Notes Payable | $34,198,000 | $146,000 | $146,000 | $146,000 |
| Payables And Accrued Expenses | $108,104,000 | $89,672,000 | $101,479,000 | $72,679,000 |
| Payables | $82,987,000 | $61,470,000 | $61,446,000 | $40,939,000 |
| Accounts Payable | $82,987,000 | $61,470,000 | $61,446,000 | $40,939,000 |
| Equity | ||||
| Common Stock Equity | $-271,111,000 | $-326,380,000 | $-160,331,000 | $-61,278,000 |
| Total Equity Gross Minority Interest | $-277,861,000 | $-306,424,000 | $-148,382,000 | $-54,902,000 |
| Stockholders Equity | $-271,111,000 | $-326,380,000 | $-160,331,000 | $-61,278,000 |
| Gains Losses Not Affecting Retained Earnings | $-439,000 | $-1,398,000 | $-955,000 | $915,000 |
| Other Equity Adjustments | $-439,000 | $-1,398,000 | $-955,000 | $915,000 |
| Retained Earnings | $-2,182,765,000 | $-2,182,880,000 | $-1,955,668,000 | $-1,709,907,000 |
| Long Term Equity Investment | $24,277,000 | $0 | - | - |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $35,320,397 | $23,634,670 | $19,718,662 | $15,278,669 |
| Share Issued | $35,320,397 | $23,634,670 | $19,718,662 | $15,278,669 |
| Tangible Book Value | $-298,240,000 | $-353,848,000 | $-189,465,000 | $-92,973,000 |
| Invested Capital | $-226,456,000 | $-293,209,000 | $-147,417,000 | $-48,119,000 |
| Working Capital | $-190,053,000 | $-175,827,000 | $-143,481,000 | $24,170,000 |
| Capital Lease Obligations | $11,244,000 | $61,699,000 | $75,555,000 | $65,269,000 |
| Total Capitalization | $-271,111,000 | $-295,907,000 | $-147,563,000 | $-48,694,000 |
| Minority Interest | $-6,750,000 | $19,956,000 | $11,949,000 | $6,376,000 |
| Additional Paid In Capital | $1,911,740,000 | $1,857,662,000 | $1,796,095,000 | $1,644,658,000 |
| Capital Stock | $353,000 | $236,000 | $197,000 | $3,056,000 |
| Common Stock | $353,000 | $236,000 | $197,000 | $3,056,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,143,000 | $1,143,000 | $1,143,000 | $1,143,000 |
| Long Term Capital Lease Obligation | $10,108,000 | $54,551,000 | $62,511,000 | $63,326,000 |
| Current Deferred Revenue | $0 | $31,000 | $18,000 | $12,269,000 |
| Current Capital Lease Obligation | $1,136,000 | $7,148,000 | $13,044,000 | $1,943,000 |
| Current Accrued Expenses | $25,117,000 | $28,202,000 | $40,033,000 | $31,740,000 |
| Duefrom Related Parties Non Current | $15,435,000 | $0 | - | - |
| Investments And Advances | $24,277,000 | $0 | - | - |
| Investmentsin Associatesat Cost | $24,277,000 | $0 | - | - |
| Goodwill | $24,092,000 | $24,092,000 | $24,723,000 | $25,467,000 |
| Net PPE | $23,214,000 | $147,395,000 | $163,027,000 | $164,286,000 |
| Accumulated Depreciation | $-47,468,000 | $-72,553,000 | $-61,943,000 | $-54,075,000 |
| Gross PPE | $70,682,000 | $219,948,000 | $224,970,000 | $218,361,000 |
| Leases | $23,605,000 | $94,860,000 | $95,645,000 | $28,758,000 |
| Construction In Progress | $56,000 | $784,000 | $1,512,000 | $66,464,000 |
| Other Properties | $7,744,000 | $27,308,000 | $29,606,000 | $31,269,000 |
| Machinery Furniture Equipment | $29,221,000 | $78,873,000 | $80,084,000 | $73,930,000 |
| Buildings And Improvements | $0 | $5,837,000 | $5,837,000 | $5,654,000 |
| Land And Improvements | $10,056,000 | $12,286,000 | $12,286,000 | $12,286,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Stock | - | - | $0 | $0 |
| Other Short Term Investments | - | - | $0 | $14,684,000 |
Fetched: 2026-07-09
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-77,201,000 | $-158,891,000 | $-234,156,000 | $-228,435,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-77,195,000 | $-158,315,000 | $-224,202,000 | $-175,373,000 |
| Cash Flow From Continuing Operating Activities | $-77,195,000 | $-158,315,000 | $-224,202,000 | $-175,373,000 |
| Operating Gains Losses | $-100,374,000 | $-4,589,000 | $-1,964,000 | $-19,802,000 |
| Investing Activities | ||||
| Capital Expenditure | $-6,000 | $-576,000 | $-9,954,000 | $-53,062,000 |
| Investing Cash Flow | $1,194,000 | $27,000 | $3,400,000 | $-33,610,000 |
| Cash Flow From Continuing Investing Activities | $1,194,000 | $27,000 | $3,400,000 | $-33,610,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-87,000 | $0 | $-5,172,000 | $-3,789,000 |
| Issuance Of Capital Stock | $36,136,000 | $38,823,000 | $133,157,000 | $99,211,000 |
| Financing Cash Flow | $36,593,000 | $122,840,000 | $119,866,000 | $95,830,000 |
| Cash Flow From Continuing Financing Activities | $36,593,000 | $122,840,000 | $119,866,000 | $95,830,000 |
| Net Other Financing Charges | $-1,974,000 | $73,851,000 | $-606,000 | - |
| Net Common Stock Issuance | $36,049,000 | $38,823,000 | $127,985,000 | $95,422,000 |
| Common Stock Issuance | $36,136,000 | $38,823,000 | $133,157,000 | $99,211,000 |
| Other | ||||
| Repayment Of Debt | $-10,151,000 | $-10,481,000 | $-8,926,000 | $-490,000 |
| Issuance Of Debt | $12,500,000 | $20,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $1,175,000 | $2,278,000 | $3,168,000 | $1,143,000 |
| End Cash Position | $4,710,000 | $44,071,000 | $79,779,000 | $181,343,000 |
| Beginning Cash Position | $44,071,000 | $79,779,000 | $181,343,000 | $294,600,000 |
| Effect Of Exchange Rate Changes | $47,000 | $-260,000 | $-628,000 | $-104,000 |
| Changes In Cash | $-39,408,000 | $-35,448,000 | $-100,936,000 | $-113,153,000 |
| Proceeds From Stock Option Exercised | $169,000 | $647,000 | $807,000 | $898,000 |
| Common Stock Payments | $-87,000 | $0 | $-5,172,000 | $-3,789,000 |
| Net Issuance Payments Of Debt | $2,349,000 | $9,519,000 | $-8,926,000 | $-490,000 |
| Net Long Term Debt Issuance | $2,349,000 | $9,519,000 | $-8,926,000 | $-490,000 |
| Long Term Debt Payments | $-10,151,000 | $-10,481,000 | $-8,926,000 | $-490,000 |
| Long Term Debt Issuance | $12,500,000 | $20,000,000 | $0 | $0 |
| Net Investment Purchase And Sale | $841,000 | $579,000 | $9,991,000 | $371,000 |
| Sale Of Investment | $841,000 | $579,000 | $30,034,000 | $25,000,000 |
| Purchase Of Investment | $0 | $0 | $-20,043,000 | $-24,629,000 |
| Net PPE Purchase And Sale | $353,000 | $-552,000 | $-6,591,000 | $-31,064,000 |
| Sale Of PPE | $359,000 | $24,000 | $3,363,000 | $21,998,000 |
| Purchase Of PPE | $-6,000 | $-576,000 | $-9,954,000 | $-53,062,000 |
| Change In Working Capital | $27,334,000 | $32,604,000 | $10,756,000 | $24,084,000 |
| Change In Other Working Capital | $-197,000 | $-671,000 | $-13,794,000 | $3,569,000 |
| Change In Payables And Accrued Expense | $27,999,000 | $2,149,000 | $41,979,000 | $8,528,000 |
| Change In Accrued Expense | $4,499,000 | $136,000 | $20,613,000 | $2,034,000 |
| Change In Payable | $23,500,000 | $2,013,000 | $21,366,000 | $6,494,000 |
| Change In Account Payable | $23,500,000 | $2,013,000 | $21,366,000 | $6,494,000 |
| Change In Prepaid Assets | $1,260,000 | $5,782,000 | $6,032,000 | $11,865,000 |
| Change In Receivables | $-1,728,000 | $25,344,000 | $-23,461,000 | $122,000 |
| Changes In Account Receivables | $-1,728,000 | $25,344,000 | $-23,461,000 | $122,000 |
| Other Non Cash Items | $-51,194,000 | $11,693,000 | $-14,140,000 | $19,607,000 |
| Stock Based Compensation | $13,770,000 | $17,390,000 | $22,869,000 | $18,337,000 |
| Unrealized Gain Loss On Investment Securities | $26,119,000 | $1,542,000 | $2,126,000 | - |
| Asset Impairment Charge | $234,000 | $1,973,000 | $0 | $6,111,000 |
| Depreciation Amortization Depletion | $9,999,000 | $13,343,000 | $13,588,000 | $6,946,000 |
| Depreciation And Amortization | $9,999,000 | $13,343,000 | $13,588,000 | $6,946,000 |
| Gain Loss On Investment Securities | $-387,000 | $-3,954,000 | $-556,000 | $-815,000 |
| Gain Loss On Sale Of Business | $-100,924,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-3,083,000 | $-232,271,000 | $-257,437,000 | $-230,656,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-2,917,000 |
| Purchase Of Business | - | $0 | $0 | $-2,917,000 |
| Change In Inventory | - | - | - | - |
Fetched: 2026-07-09